How many chemotherapy regimens are available for patients with non-Hodgkin’s lymphoma? There are more than 70 types of lymphoma and each type has different treatment options that are very complex. As an example: diffuse large B-cell lymphoma is very common, and nearly 40%-50% of patients with non-Hodgkin’s lymphoma are of this type. Zhang Huilai, Department of Medical Oncology, Tianjin Cancer Hospital Mr. Kai-Fu Li, CEO of Innovation Works, and Mr. Jing Luo of CCTV, who has passed away, are both patients with diffuse large B-cell lymphoma. The first-line treatment regimen for this part of patients is mainly based on rituximab combined with CHOP regimen, which we call RCHOP regimen. Speaking of the RCHOP regimen, which drugs does it consist of, and is it a combination of these drugs for each chemotherapy treatment? Yes. The RCHOP regimen is the standard first-line treatment for diffuse large B-cell lymphoma and consists of rituximab, cyclophosphamide, anthracycline adriamycin, vincristine, and prednisone hormone. Drug doses may have some fine-tuning depending on the patient’s physical condition, bone marrow function, and liver and kidney function. Why is the dose different for two chemotherapy sessions with the same drugs? The dose of each chemotherapy treatment is adjusted according to the drug toxicity of the previous chemotherapy cycle. Chemotherapy drugs are highly toxic to the body, the most prominent being bone marrow toxicity. After applying chemotherapy drugs, the patient’s bone marrow hematopoietic function will be suppressed and white blood cells, red blood cells and platelets will drop. The more concern after chemotherapy is the decline of white blood cells, which will affect the course of chemotherapy. The rule of white blood cell decline is: the patient’s white blood cell will not drop immediately after chemotherapy, but usually starts to drop on the 7th day after chemotherapy; it will drop to the lowest point on the 10th to 14th day after chemotherapy; after the 14th day, the white blood cell will gradually recover; and the patient will receive the next cycle of treatment on the 21st day. For example, if the patient is one degree myelotoxic after chemotherapy and the white blood cell is (3.0~3.9)*109/L, the dose of chemotherapy drug will not be adjusted; if the patient is three or four degree myelotoxic after chemotherapy, and also combined with fever and diarrhea, the patient’s chemotherapy dose will be reduced by 25%~50%. This article is an original work and may not be reproduced without authorization.